Manuscripts
Showing 1554 manuscripts.
Molecular detection of Mycobacterium tuberculosis from stool in young children using a novel centrifugation-free processing method
Citation
P Nabeta, AM Demers, G Reubenson, C Bosch, A David, M van der Zalm, J Havumaki, M Palmer, AC Hesseling, J Ncayiyana, W Stevens, D Alland, C Denkinger, P Banada, E Walters, L Scott. Molecular detection of Mycobacterium tuberculosis from stool in young children using a novel centrifugation-free processing method. Journal of Clinical Microbiology. 2018. 56: e00781-18. PMID: 29997199Year
2018
Journal
Journal of Clinical Microbiology
Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV
Citation
Jiajia Wang, Edmund V Capparelli, Alice Stek, Emily Barr, Martina L Badell, Edward P Acosta, Murli Purswani, Elizabeth Smith, Nahida Chakhtoura, Kyunghun Park, Sandra Burchett, David E Shapiro, Mark Mirochnick, Jeremiah D Momper, Brookie M Best, IMPAACT P1026s Protocol Team. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS. 2018. 32: 2507-2516. PMID: 30134297Year
2018
Journal
AIDS
Study
P1026S
Development and application of a multiplex assay for the simultaneous measurement of antibodyresponses elicited by common childhood vaccines.
Citation
CK Cunningham, EJ McFarland, W Borkowsky, SR Permar, GG Fouda, HL Itell, EP McGuire. Development and application of a multiplex assay for the simultaneous measurement of antibodyresponses elicited by common childhood vaccines.. Vaccine. 2018. 36: 5600-5608. PMID: 30087048Year
2018
Journal
Vaccine
Metabolic effects of initiating lopinavir/ritonavir-based regimens among young children.
Citation
K Angelidou, G Aldrovandi, P Palumbo, IMPAACT P1060 Study team, K Patel, J Lindsey. Metabolic effects of initiating lopinavir/ritonavir-based regimens among young children.. AIDS. 2018. 32: 2327-2336. PMID: 30102656Year
2018
Journal
AIDS
Study
P1060
Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood
Citation
Brookie M Best, Jorge Pinto, Ellen G Chadwick, Eric S Daar, Peter L Havens, Natella Rakhmanina, Edmund V Capparelli, Jincheng Yang, Mina Nikanjam. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood. Journal of Clinical Pharmacology. 2018. 58: 1604-1617. PMID: 30252146Year
2018
Journal
Journal of Clinical Pharmacology
Study
P1083, P1030, P1038
Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children.
Citation
Moscicki AB, Saah A, Levin MJ, IMPAACT P1085 Protocol Team, Weinberg A, Huang S. Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children.. AIDS. 2018. 32: 851-860. PMID: 29424778Year
2018
Journal
AIDS
Study
P1085
Quantification of variation and the impact of biomass in targeted 16S rRNA gene sequencing studies.
Citation
H Adisetivo, D Lee, S Zabih, L Hung, TA Wiklinson, PS Pannaraj, RC She, JD Bard, NH Tobin, GM Aldrovandi, JM Bender, F Li. Quantification of variation and the impact of biomass in targeted 16S rRNA gene sequencing studies.. Microbiome. 2018. 6: 155. PMID: 30201048Year
2018
Journal
Microbiome
Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations.
Citation
KA Lee-Sarwar, HM Tun, BP Brown, PS Pannaraj, JM Bender, MB Azad, AL Thompson, ST Weiss, MA Azcarate-Peril, AA Litonjua, AL Kozyrskyi, HB Jaspan, GM Aldrovandi, L Kuhn, NT Ho, F Li. Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations.. Nature Communications. 2018. 9: 4169. PMID: 30301893Year
2018
Journal
Nature Communications
Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.
Citation
B Homony, H Teppler, AJ Rodgers, BL Graham, T Fenton, LM Frenkel, RS Browning, R Hazra, AA Wiznia, IMPAACT 1066 Study Team, S Nachman, C Alvero. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.. Lancet HIV. 2018. 5: e715-e722. PMID: 30527329Year
2018
Journal
Lancet HIV
Study
P1066